首页 > 市场调查报告书 > 製药

DDS

市场调查报告书

商品编码

1548178

全球吸入药物市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势和预测

Global Inhalable Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年08月01日 | 出版商:

Value Market Research | 英文 128 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球吸入药物市场需求预计将从 2023 年的 392.1 亿美元达到近 734.3 亿美元的市场规模，2024-2032 年研究期间复合年增长率为 7.22%。

可吸入药物是设计为透过吸入给药的药物，通常透过吸入器或雾化器等装置。这些药物被配製为将治疗剂直接输送到呼吸道，在那里它们可以发挥局部作用，例如减少发炎或扩张气道。这些药物通常用于治疗气喘和慢性阻塞性肺病 (COPD) 等慢性呼吸系统疾病，包括多种类别，例如支气管扩张剂、皮质类固醇和联合疗法。这些药物的有效性取决于它们是否能精确有效地输送到肺部，从而提高治疗效果并最大限度地减少全身副作用。吸入器技术和药物配方的创新不断提高这些治疗的功效和便利性，满足呼吸系统疾病患者的复杂需求。

市场动态

气喘和慢性阻塞性肺病等慢性呼吸道疾病的发生率不断上升，推动了吸入药物市场的发展，这些疾病在不同的人群中普遍存在。人们对非侵入性治疗方案的认识和偏好不断提高，推动了对吸入药物的需求，因为它们提供具有最小全身影响的标靶治疗。吸入器设备的技术进步，包括具有整合数位健康功能的智慧吸入器，透过提高患者依从性和优化药物输送，为市场成长开闢了新的途径。此外，对个人化医疗的日益重视以及生物製剂和联合疗法等新型吸入製剂的开发，为市场扩张提供了重大机会。新兴市场医疗保健服务的成长以及呼吸系统疾病研究投资的增加进一步促进了市场的成长。加强病患教育和支持计画也提高了吸入药物疗法的整体有效性和采用率。然而，先进的吸入药物製剂和设备的高成本可能会抑制吸入药物市场的成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球吸入药物市场的各个细分市场进行了包容性评估。吸入药物产业的成长和趋势为本研究提供了整体方法。

市场区隔

吸入药物市场报告的这一部分提供了有关国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人口统计数据以及即将到来的机会。

按药物类别

气雾剂
干粉製剂
喷

按申请

呼吸系统疾病
非呼吸系统疾病

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲的吸入药物市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。吸入药物市场的主要参与者包括阿斯特捷利康、赛诺菲、Vectura Group Ltd、Viatris Inc.、GSK Plc.、Mundipharma International.、Boehringer Ingelheim International GmbH.、Cipla Inc.。，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区按国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲按国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 8 章：吸入药品公司的竞争格局

吸入药物市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 9 章：公司简介

顶级公司市占率分析
市场集中度
AstraZeneca

公司概况
公司收入
产品
最新动态

Sanofi

公司概况
公司收入
产品
最新动态

Vectura Group Ltd

公司概况
公司收入
产品
最新动态

Viatris Inc.

公司概况
公司收入
产品
最新动态

GSK Plc.

公司概况
公司收入
产品
最新动态

Mundipharma International.

公司概况
公司收入
产品
最新动态

Boehringer Ingelheim International GmbH.

公司概况
公司收入
产品
最新动态

Cipla Inc

公司概况
公司收入
产品
最新动态

註 - 在公司概况中，财务详细资讯和最新发展视情况而定，或对私人公司而言可能不包括在内

简介目录图表

Product Code: VMR112115512

The global demand for Inhalable Drugs Market is presumed to reach the market size of nearly USD 73.43 Billion by 2032 from USD 39.21 Billion in 2023 with a CAGR of 7.22% under the study period 2024-2032.

Inhalable drugs are medications designed to be administered via inhalation, typically through devices such as inhalers or nebulizers. These drugs are formulated to deliver therapeutic agents directly to the respiratory tract, where they can exert localized effects, such as reducing inflammation or dilating airways. Commonly used in treating chronic respiratory conditions like asthma & chronic obstructive pulmonary disease (COPD), these drugs include various classes, such as bronchodilators, corticosteroids, and combination therapies. The effectiveness of these medications hinges on their ability to achieve precise and efficient delivery to the lungs, thereby enhancing therapeutic outcomes and minimizing systemic side effects. Innovations in inhaler technology and drug formulations continue to advance these treatments' efficacy and convenience, catering to the complex needs of patients with respiratory ailments.

MARKET DYNAMICS

The inhalable drugs market is bolstered by the propelling incidence of chronic respiratory diseases, such as asthma & COPD, which are prevalent across diverse demographics. The increasing awareness & preference for non-invasive treatment options drive demand for inhalable drugs, as they offer targeted therapy with minimal systemic effects. Technological advancements in inhaler devices, including smart inhalers with integrated digital health capabilities, are opening new avenues for market growth by improving patient adherence and optimizing drug delivery. Moreover, the rising emphasis on personalized medicine & the development of novel inhalable formulations, such as biologics and combination therapies, present significant opportunities for market expansion. The growth of healthcare access in emerging markets & the rising investment in respiratory disease research further contribute to the market growth. Increased efforts in patient education and support programs also enhance the overall effectiveness and adoption of inhalable drug therapies. However, the high cost of advanced inhalable drug formulations and devices may restrain inhalable drug market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Inhalable Drugs. The growth and trends of Inhalable Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Inhalable Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Aerosol
Dry Powder Formulation
Spray

By Application

Respiratory Diseases
Non-respiratory Disease

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Inhalable Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Inhalable Drugs market include AstraZeneca, Sanofi, Vectura Group Ltd, Viatris Inc., GSK Plc., Mundipharma International., Boehringer Ingelheim International GmbH., Cipla Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. INHALABLE DRUGS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL INHALABLE DRUGS MARKET ANALYSIS BY DRUG CLASS

5.1. Overview By Drug Class
5.2. Historical and Forecast Data Analysis By Drug Class
5.3. Aerosol Historic and Forecast Sales By Regions
5.4. Dry Powder Formulation Historic and Forecast Sales By Regions
5.5. Spray Historic and Forecast Sales By Regions

6. GLOBAL INHALABLE DRUGS MARKET ANALYSIS BY APPLICATION

6.1. Overview By Application
6.2. Historical and Forecast Data Analysis By Application
6.3. Respiratory Diseases Historic and Forecast Sales By Regions
6.4. Non-respiratory Disease Historic and Forecast Sales By Regions

7. GLOBAL INHALABLE DRUGS MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE INHALABLE DRUGS COMPANIES

8.1. Inhalable Drugs Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF INHALABLE DRUGS INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. AstraZeneca
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. Sanofi
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. Vectura Group Ltd
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. Viatris Inc.
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. GSK Plc.
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. Mundipharma International.
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. Boehringer Ingelheim International GmbH.
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments
9.10. Cipla Inc
- 9.10.1 Company Overview
- 9.10.2 Company Revenue
- 9.10.3 Products
- 9.10.4 Recent Developments